<SEC-DOCUMENT>0001193125-24-101096.txt : 20240419
<SEC-HEADER>0001193125-24-101096.hdr.sgml : 20240419
<ACCEPTANCE-DATETIME>20240418185726
ACCESSION NUMBER:		0001193125-24-101096
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20240418
FILED AS OF DATE:		20240419
DATE AS OF CHANGE:		20240418

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		24855289

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d830354d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as April 18, 2024 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form
40-F&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(1):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule
101(b)(7):&#8194;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d830354dex991.htm">Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761 </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: April 18, 2024 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d830354dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830354dsp0004.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Appoints Leading Research Institute to Conduct </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">First-in-Human</FONT></FONT> Phase I Study of IMP761 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Centre for Human Drug Research (CHDR) will conduct Phase I trial to evaluate IMP761, a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody designed to restore balance to the immune system and address the underlying cause of autoimmune
diseases</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>CHDR will utilize its unique challenge model that enables insights into IMP761&#146;s pharmacological activity
early in clinical development</I> </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>Trial expected to begin <FONT STYLE="white-space:nowrap">mid-CY2024</FONT></I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; 18</B><B></B><B>&nbsp;April </B><B>2024 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a clinical-stage biotechnology company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapies for cancer and autoimmune disease, today announces it has entered into an agreement with the <U>Centre
for Human Drug Research (CHDR)</U>, a world-class institute in Leiden, the Netherlands specializing in cutting-edge early-stage clinical drug research, to perform a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> clinical study of IMP761. This proprietary <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody has been designed to restore balance to the
immune system and address the underlying cause of many autoimmune diseases. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to the relevant ethic and regulatory approvals, the single and
multiple ascending dose, placebo-controlled, double-blind, Phase I study will enrol approximately 49 healthy volunteers, with the objective of assessing safety, pharmacokinetics (PK) and pharmacodynamics (PD). The study will implement CHDR&#146;s
unique keyhole limpet haemocyanin (KLH) challenge model that allows for the evaluation of immunomodulatory agents&#146; pharmacological activity at the earliest stages of clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s Chief Scientific Officer, Fr&eacute;d&eacute;ric Triebel, M.D., Ph.D., stated, &#147;IMP761 is a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> <FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody developed to reinforce the dampening of T cell responses in autoimmunity. The phase I trial in healthy subjects is designed to
establish clear PK/PD relationships at different dose levels, with a placebo control group, to lay the foundation for the future development of this novel immunotherapy. We are excited to leverage CHDR&#146;s expertise in working with targeted
immunotherapy candidates in the clinical setting to evaluate IMP761&#146;s potential in changing how autoimmune disorders are treated.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthijs
Moerland, Ph.D., CHDR&#146;s Research Director Immunology and Principal Investigator for the upcoming trial, said, &#147;It is an honour for us to run the first clinical study with IMP761. We&#146;re very excited to be partnering with Immutep for
this critical step in the development plan of their promising antibody. We are confident that CHDR&#146;s unique neoantigen KLH challenge model will help define and measure by dose levels its pharmacological activity in man.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immune checkpoint agonists, including <FONT STYLE="white-space:nowrap">LAG-3,</FONT> <FONT STYLE="white-space:nowrap">PD-1,</FONT> and <FONT
STYLE="white-space:nowrap">CTLA-4,</FONT> are increasingly gaining recognition in the healthcare industry for their inherent ability to treat autoimmune diseases.<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> In numerous scientific
publications, <FONT STYLE="white-space:nowrap">LAG-3</FONT> has been identified as a promising target for agonist immunotherapy for autoimmune disorders including rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis, among others.<SUP
STYLE="font-size:75%; vertical-align:top">2,3,4</SUP> </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g830354dsp0004.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761 is uniquely positioned as the world&#146;s first immunosuppressive
<FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody. It may address numerous autoimmune diseases by silencing self-antigen-specific memory T cells, which accumulate at disease sites, and preventing their overactivation. This is
accomplished through enhancing <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> natural downregulation of auto-reactive memory T cells.&nbsp;IMP761 remains on target to enter the clinic <FONT STYLE="white-space:nowrap">mid-CY2024</FONT> and
Immutep looks forward to providing more information as it approaches this important milestone. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About&nbsp;IMP761 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP761, a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> immunosuppressive
<FONT STYLE="white-space:nowrap">LAG-3</FONT> agonist antibody, has the potential to address the root cause of many autoimmune diseases by specifically silencing autoimmune memory T cells that accumulate at disease sites and restoring balance to the
immune system. As published in the&nbsp;<U>Journal of Immunology</U>, encouraging <FONT STYLE="white-space:nowrap">pre-clinical</FONT> <I>in vivo </I>and<I> in vitro</I> studies show IMP761 inhibits peptide-induced T cell proliferation, activation
of human primary T cells, and an antigen-specific delayed-type hypersensitivity (DTH) reaction. Additional preclinical data in oligoarticular juvenile idiopathic arthritis <FONT STYLE="white-space:nowrap">(o-JIA)</FONT> published
in&nbsp;<U>Pediatric&nbsp;Research</U> details how&nbsp;IMP761&nbsp;led to a decrease in a broad spectrum of effector cytokines in just 48&#8201;hours. This study also showed children with <FONT STYLE="white-space:nowrap">o-JIA</FONT> have a skewed <FONT
STYLE="white-space:nowrap">LAG-3</FONT> metabolism and suggested they can benefit from agonistic <FONT STYLE="white-space:nowrap">LAG-3</FONT> activity. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a clinical-stage biotechnology
company developing novel <FONT STYLE="white-space:nowrap">LAG-3</FONT> immunotherapy for cancer and autoimmune disease. We are pioneers in the understanding and advancement of therapeutics related to Lymphocyte Activation <FONT
STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and our diversified product portfolio harnesses its unique ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its
expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong, Morrow
Sodali </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>c.strong@morrowsodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor
Relations and Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Grebinoski S, Vignali DA. Inhibitory receptor agonists: the future of autoimmune disease therapeutics? Curr Opin Immunol. 2020 Dec;67:1-9. doi:
10.1016/j.coi.2020.06.001. Epub 2020 Jun 30. PMID: 32619929; PMCID: PMC7744338. </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. Pedersen, J.M., Hansen, A.S., Skej&oslash;, C. et al. Lymphocyte
activation gene 3 is increased and affects cytokine production in rheumatoid arthritis. Arthritis Res Ther 25, 97 (2023). <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://doi.org/10.1186/s13075-023-03073-z</FONT></FONT>
</I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. Jones BE, Maerz MD et al. Fewer <FONT STYLE="white-space:nowrap">LAG-3+</FONT> T Cells in Relapsing-Remitting Multiple Sclerosis and Type 1
Diabetes. J Immunol. 2022 Feb <FONT STYLE="white-space:nowrap">1;208(3):594-602.</FONT> doi: 10.4049/jimmunol.2100850. Epub 2022 Jan 12. PMID: 35022272; PMCID: PMC8820445. </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>4. Zhou X, Gu Y et al. From bench to bedside: targeting lymphocyte activation gene 3 as a therapeutic strategy for autoimmune diseases. Inflamm Res. 2023
Jun;72(6):1215-1235. doi: <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10.1007/s00011-023-01742-y.</FONT></FONT></FONT> Epub 2023 Jun 14. PMID: 37314518. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g830354dsp0004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g830354dsp0004.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H 0
M\4 <]KGBB/2Y#;P();@=<GY4^M9SJ<IS5:ZAHC"B\6ZPQ\P11.FX+@(>I[=:
MS521SK$U'L=?INJ"]#Q2Q-;W48&^%^H]QZBMHRON=T)\VCW- 5184 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 9 H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!Q7B;3_ !1<Z]%+I<KK:J!MV2A0I[[AGG]: .S0,$ ;[V.<
M4 .H * "@ H * "@ H * "@ H * "@"*ZG%K:33D$B)"Y [X&: .:\/>,AK^
MJO9I9&%%C,FYGR3@@8QCWH ZJ@ H * "@ H * $(R* //M3\/_V?J9EE\P:>
MS$B2,9*>Q]/K7/*/*[GG3H\D[O8H7>O:E= Q&Z?RL\* !QVSBIYFS*563T.@
M\-Z/=2:@=5O8_+.,HN,$DC&<=N*TA!WNSIH4I.7/([&MCM"@ H * "@ H *
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M@#T:WG@O;:.>%Q)%(H92.A!H 1;*U1]ZVT0?^\$&:5D3RI="?&*904 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MTWX>:793K-<2273*<A7P%_$#K0!UP4*  ,"@!: "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H KP7!EN;F(J (6"
M@^N5!_K0!#+J BU&.VVY0@!W_NL<[1^.T_IZT (]S<27<T-MY:K"!O>3)Y(S
M@ >V.?>@"T)D^5#(GF,,@ ]?I0!5M;R22_GM9#&QC4-E 1C)/'/7IUH FFN&
MBN[>$*")2P)],#- %./6,K=[XL/$Y6)0?]8-Q4?CN&/R]: $.KO';V$SQ#;.
MNZ7!_P!6,#)]P"1^% $UOJ#3ZA<6X3]W$HVOG[YR0WY'CZYH (K]Y+?39-@!
MN\9&?NYC+<?EB@"N^LM&M]OB"M!O,7/$FT9(]C[?_7P 6YKF=KS[+;! ZH)'
M=\D $D 8'7H?RH 8MY<26L[*L:3P,5=3DKP,\?4$?G0 TZA)#96EQ<>6!.R@
MD9 4$9H 235A]GU"6':ZVL>\'/WCM)Q^E "_;W33[JY\R&7R49@$! X&><T
M+8Z@US<O"7AF54#>9"<@'T/H?QH =;:B9KZ2$H%BY\I\_?VG#?3!/XT 5O[6
MD%R4S P\_P GR@W[P#.-W]?I0!.FH2-=?9/+ G#_ ##L(^S?CT^N?2@#F_B7
M_P @.T_Z^!_Z": +7P\_Y%=?^NS_ -* .KH * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * *GV)ENGGCN)4\
MP@L@"D'  [C/0>M $4FCVLOFN\8,TC[_ #<#>A&,8/;&!0 ^;3_,E>1)Y(3(
MNU]FW#>G4'F@">*W2**-%'^K4*K'K@4 10V7EW7VAYI)9 I0%MHP#R>@'H*
M)9;=9)XI23F+)7'N,4 0IIUNAC<IN>)W=&)Y!8DG^= "1Z;"B1(=S+%&T8#=
M"&QG/Y4 /AL(;>1&B!4)'Y87/&,YH B@TQ87@_?RO';_ .JC;&%X([#)P"1R
M: "XTJ"YM9[>3<5F<N2#RI/I0!+-9>9,L\<SPRA=I9,?,/0Y!H 6&S2&V>$,
MS;R2[L>6)ZF@ -FGDVT>6Q;D%?? QS^= #9;".9+M69@+E-CX(X&,<?G0 C6
M326TT$US+*DJ%#N"@@$8XP!0 \6BK<-,C,C,FQL8P?0_44 01Z/9P"W,,*QR
M0$$.H 8\8.3WSF@"S;VR6^_;D[W+DGU)S0 JVZK=-<9.YD"8[8!)_K0!0UW0
M;;7[6.WNI)42-]X,9 .<$=P?6@"31='@T.P%G;/(\88MF0@G)^@% &C0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M)W_U#_\ R+_]:CVH?6_(/^$[_P"H?_Y%_P#K4>U#ZWY!_P )W_U#_P#R+_\
M6H]J'UOR#_A._P#J'_\ D7_ZU'M0^M^0?\)W_P!0_P#\B_\ UJ/:A];\@_X3
MO_J'_P#D7_ZU'M0^M^0?\)W_ -0__P B_P#UJ/:A];\@_P"$[_ZA_P#Y%_\
MK4>U#ZWY!_PG?_4/_P#(O_UJ/:A];\@_X3O_ *A__D7_ .M1[4/K?D'_  G?
M_4/_ /(O_P!:CVH?6_(/^$[_ .H?_P"1?_K4>U#ZWY!_PG?_ %#_ /R+_P#6
MH]J'UOR#_A._^H?_ .1?_K4>U#ZWY!_PG?\ U#__ "+_ /6H]J'UOR#_ (3O
M_J'_ /D7_P"M1[4/K?D'_"=_]0__ ,B__6H]J'UOR#_A._\ J'_^1?\ ZU'M
M0^M^0?\ "=_]0_\ \B__ %J/:A];\@_X3O\ ZA__ )%_^M1[4/K?D'_"=_\
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M\@_X3O\ ZA__ )%_^M1[4/K?D'_"=_\ 4/\ _(O_ -:CVH?6_(/^$[_ZA_\
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M (3O_J'_ /D7_P"M1[4/K?D'_"=_]0__ ,B__6H]J'UOR#_A._\ J'_^1?\
MZU'M0^M^0?\ "=_]0_\ \B__ %J/:A];\@_X3O\ ZA__ )%_^M1[4/K?D'_"
M=_\ 4/\ _(O_ -:CVH?6_(/^$[_ZA_\ Y%_^M1[4/K?D'_"=_P#4/_\ (O\
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MJU,/^$,TOUF_[[_^M1[*(?5J8?\ "&:7ZS?]]_\ UJ/91#ZM3#_A#-+]9O\
MOO\ ^M1[*(?5J8?\(9I?K-_WW_\ 6H]E$/JU,/\ A#-+]9O^^_\ ZU'LHA]6
MIA_PAFE^LW_??_UJ/91#ZM3#_A#-+]9O^^__ *U'LHA]6IA_PAFE^LW_ 'W_
M /6H]E$/JU,/^$,TOUF_[[_^M1[*(?5J8?\ "&:7ZS?]]_\ UJ/91#ZM3#_A
M#-+]9O\ OO\ ^M1[*(?5J8?\(9I?K-_WW_\ 6H]E$/JU,/\ A#-+]9O^^_\
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M *U'LHA]6IA_PAFE^LW_ 'W_ /6H]E$/JU,/^$,TOUF_[[_^M1[*(?5J8?\
M"&:7ZS?]]_\ UJ/91#ZM3#_A#-+]9O\ OO\ ^M1[*(?5J8?\(9I?K-_WW_\
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M^$,TOUF_[[_^M1[*(?5J8?\ "&:7ZS?]]_\ UJ/91#ZM3#_A#-+]9O\ OO\
M^M1[*(?5J8?\(9I?K-_WW_\ 6H]E$/JU,/\ A#-+]9O^^_\ ZU'LHA]6IA_P
MAFE^LW_??_UJ/91#ZM3#_A#-+]9O^^__ *U'LHA]6IA_PAFE^LW_ 'W_ /6H
M]E$/JU,/^$,TOUF_[[_^M1[*(?5J8?\ "&:7ZS?]]_\ UJ/91#ZM3#_A#-+]
M9O\ OO\ ^M1[*(?5J8?\(9I?K-_WW_\ 6H]E$/JU,/\ A#-+]9O^^_\ ZU'L
7HA]6IA_PAFE^LW_??_UJ/91#ZM3/_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
